Peripheral neuropathic pain (PNP), resulting from injury to or dysfunction of a peripheral nerve, is a major health problem that affects 7-8% of the population. It is inadequately controlled by current drugs and is characterized by pain hypersensitivity, which is believed to be attributable to sensitization of peripheral and CNS neurons by various inflammatory mediators. Here we examined, in a rat model of PNP: (i) whether reducing levels of nitric oxide (NO) with 1400W, a highly selective inhibitor of inducible NO synthase (iNOS), would prevent or attenuate pain hypersensitivity; and (ii) the effects of 1400W on plasma concentrations of several cytokines that are secreted after iNOS upregulation during chronic pain states. The L5 spinal nerve axotomy (SNA) model of PNP was used, and 1400W (20 mg kg −1 ) was administered I.P. at 8 h intervals for 3 days starting at 18 h post-SNA. Changes in plasma concentrations of 12 cytokines in SNA rats treated with 1400W were examined using multiplex enzyme-linked immunosorbent assay. The The findings suggest that 1400W might exert its analgesic effects by reducing iNOS and altering the balance between the pro-inflammatory (IL-1 and IL-1 ) and anti-inflammatory (IL-10) cytokines and that therapies targeting NO or its enzymes might be effective for the treatment of PNP.
INTRODUCTION
Chronic peripheral neuropathic pain (PNP) is defined as pain resulting from nerve dysfunction or lesion of the somatosensory system and affects approximately 7-8% of the general population (Bouhassira & Attal, 2016) . In humans, PNP is presented in the clinic by spontaneous/ongoing pain and hypersensitivity to normally painful stimuli (hyperalgesia) or non-painful stimuli (allodynia; Bonica, 1990) .
Peripheral neuropathic pain is inadequately controlled by currently available drugs, most of which lack efficacy and/or have adverse sideeffects. Despite its clinical importance, the underlying mechanisms of PNP are not fully understood. However, preclinical studies using animal models of PNP, including the L5 spinal nerve axotomy (SNA) rat model (Kim & Chung, 1992) , suggest that PNP is attributable to sensitization of both primary afferent nociceptive neurons (peri- • What is the main finding and its importance?
Nitric oxide synthase-based therapies could be effective for the treatment of peripheral neuropathic pain.
induce prolonged iNOS transcription in response to nerve injury (Aley, McCarter, & Levine, 1998; Amitai, 2010; Benarroch, 2011; Bradman, Arora, Morris, & Thippeswamy, 2010) . Nitric oxide has also been shown to mediate neuronal hyperexcitability in the chronic constriction injury pain model (Makuch, Mika, Rojewska, Zychowska, & Przewlocka, 2013; Mukherjee, Cinelli, Kang, & Silverman, 2014) .
Pro-inflammatory cytokines have been shown to be correlated with pain severity in chronic pain states (Koch et al., 2007; Leung & Cahill, 2010; Marchand, Perretti, & McMahon, 2005; Uceyler & Sommer, 2008; Uceyler et al., 2006) . The NO and, in turn, cytokines produced post-injury sensitize neurons and exacerbate hypersensitivity (von Hehn et al., 2012) . We hypothesized that at an early stage after nerve injury, reducing levels of NO specifically produced by iNOS, using 1400W, a highly selective inhibitor of iNOS (Tang et al., 2007) , would prevent development of pain hypersensitivity, which is believed to result from hyperexcitability of both peripheral and CNS neurons and also reduce the milieu of cytokines produced post-injury which could exacerbate this hypersensitivity. This hypothesis was based on our recent findings that 1400W significantly reduced neuronal hyperexcitability in a rodent model of temporal lobe epilepsy (Puttachary et al., 2016) , as well as a study by Makuch et al. (2013) showing 1400W to be effective in a chronic constriction injury pain model.
We tested this hypothesis in the SNA rat model of PNP that exhibits behavioural signs of allodynia and hyperalgesia, which are similar to the clinical signs observed in human patients with peripheral neuropathy (Chung, Kim, & Chung, 2004) . We also examined the impact of 1400W on the plasma concentration of several cytokines that are upregulated during chronic pain states. We used 1400W because it has been shown to be efficacious in reducing NO levels both in vivo and in vitro (Garvey et al., 1997) and it is a promising agent in other neurological conditions, including traumatic brain injury (Jafarian-Tehrani et al., 2005) , temporal lobe epilepsy (Puttachary et al., 2016) and chronic constriction injury, whereby 1400W enhanced the anti-nociceptive effects of morphine (Makuch et al., 2013) .
METHODS

Ethical approval
All experimental procedures were performed under a UK Home Office licence and complied with the UK Animals (Scientific Procedures) Act 1986 (establishment licence X70548BEB and project licence 40/3401) and were ethically approved by the University's Animal Welfare Committee. All the experiments also conform to the principles and regulations, as described in the Editorial by Grundy (2015) . Adult male Wistar rats (180-280 g) purchased from Charles River, UK were housed in a temperature-controlled room (22-25 • C) with food and water ad libitum on a 12 h-12 h light-dark cycle in the University of Liverpool animal facilities. A total of 22 rats were used for this study, as follows: naive + vehicle n = 3; naive + 1400W n = 3; L5-SNA + vehicle n = 7; and L5-SNA + 1400W n = 9. The investigators of this study fully understand the ethical principles under which this journal operates, and all the work carried out in this study complied with the animal ethics checklist.
Preparation of the SNA model of PNP
The L5-SNA surgery was performed under deep anaesthesia in sterile and aseptic conditions. The SNA model was produced by tight ligation and transection of the left L5 spinal nerve using a modification of the procedure described originally by Kim & Chung (1992) . Briefly, under gaseous isoflurane anaesthesia (1:1 ratio of O 2 to N 2 O, 2l min −1 ), rats were placed in a prone position, the surgical site (lumbar spine) was prepared and Videne antiseptic cream applied. The hip bone was located and a paramedian incision made through the lumbar epaxial muscles to expose the spinal processes of the vertebrae, including the L6 transverse process. Using a sterile bone cutter, part of the L6 transverse process was removed to allow access to the L4-L5 spinal nerves. The L5 spinal nerve was exposed. A tight ligature was placed around the nerve with a 6-0 silk suture (Ethicon, Brussels, Belgium; Look, Taunton, UK), and the nerve was cut distal to the suture to prevent regeneration. Using a polysorb thread, the muscles were sutured before the skin incision was stapled.
The L5-SNA rats were randomly divided into two groups. The experimental group was treated with 1400W, whereas the vehicle control group received an equal volume of physiological saline. A separate sham-operated group was not used for this study because previous studies have found no significant phenotypic differences in both mechanical and thermal hypersensitivity between L5-SNA sham rats and the normal unoperated naive rats (Djouhri, 2006; Djouhri, Fang, Koutsikou, & Lawson, 2012; Ma et al., 2003) . No other drugs were administered after surgery as this was justified in the Home Office project licence on the grounds that postoperative analgesia would impact the experimental results owing to the possible effects on the complex physiological processes that result in the formation of chronic pain. 1400W (N-[[3-(aminomethyl) phenyl]methyl]-ethanimidamide dihydrochloride; Tocris Bioscience, Bristol, UK) or vehicle (physiological saline) was administered I.P. at 5 ml kg −1 beginning at 18 h post-L5 SNA. Treatment with 1400W (20 mg kg −1 ) or administration of vehicle was repeated at 8 h intervals for the first 3 days postsurgery. Injections were given after behavioural testing had been performed; this was to ensure that the behavioural responses were not affected by any stress or discomfort attributable to scruffing or injection. The optimal dose of 1400W was determined based on pilot studies of dose-response experiments. The rationale for the treatment regimen was based on previous studies by Parmentier et al. (1999) and Pearse, Chatzipanteli, Marcillo, Bunge, and Dietrich (2003) stating that iNOS activity develops approximately 18-24 h post-insult, and the 8 h interval between doses was chosen because it has been shown that the ability of 1400W to suppress iNOS was detectable at 6 h but inefficient at 9 h. In this study, we did not aim to block iNOS activity completely but rather to suppress the pathological levels of iNOS-mediated NO production after nerve injury. The dosage and treatment course have been shown to be effective in iNOS suppression and in reducing neuropathological outcomes in various experimental models (Garvey et al., 1997; Parmentier et al., 1999; Puttachary et al., 2016) .
Drug administration
Behavioural sensory testing
All the rats used in the present study maintained good health and normal levels of exploratory, feeding and grooming activities, and their weight gain during the course of the experiment was indistinguishable from that of naive rodents. The behavioural tests were performed in specialized behaviour testing chambers (Ugo Basile, Comerio, Italy).
All animals were acclimatized to the cages, and nociceptive responses were performed after exploratory and grooming behaviours had stopped. We assessed responses to both mechanical and heat stimuli to assess mechanical and thermal hypersensitivity, the two forms of evoked pain behaviours that are routinely observed in clinical pain settings (Backonja & Stacey, 2004; Kim, Yoon, & Chung, 1997) . The stimuli were applied to the mid-plantar surface of the ipsilateral hindpaw (L4 dermatome), avoiding the footpads. Habituation was performed 2-3 days before testing for the baseline pain values (pre-SNA). Assessments for the baseline values were carried out 1 day before SNA surgery. Pain behavioural tests were also conducted every 8 h starting at 18 h post-L5 SNA for 3 days, followed by every 24 h for 10 days. The researcher who carried out the behavioural studies was blinded to the drug treatment, and comparisons between painrelated behaviours were made in two groups only: 1400W-treated and vehicle-treated L5 SNA rats. For each behavioural test, each stimulus was applied four times, and the mean ± SD values for each time point was calculated for all the groups. The two forms of evoked pain (mechanical and heat hypersensitivity) were assessed by measuring the following parameters.
Withdrawal threshold to mechanical stimulus
The automated von Frey/dynamic plantar electronic aesthesiometer (Ugo Basile) was used to evaluate mechanical hypersensitivity (mechanical allodynia). A blunt probe was applied at increasing force intensities, from 0 to 50 g over 15 s, through an elevated mesh floor, to the plantar surface of the animal's hindpaw whilst the rat was held in a Perspex cage. Tests were repeated four times, and the mean of these trials was used for each time point for each rat. The withdrawal threshold was recorded (in grams). Mechanical hypersensitivity was inferred from the decreased mean paw withdrawal thresholds (PWTs)
to a mechanical stimulus, as described previously (Weng, Smith, Sathish, & Djouhri, 2012).
Withdrawal latency to noxious heat
As described previously (Djouhri, 2006; Weng et al., 2012) , heat hypersensitivity/hyperalgesia was inferred from a decrease in the mean paw withdrawal latency (in seconds) to the heat stimulus using a
Hargreaves analgesiometer (Ugo Basile). Each rat was placed on a 2-mm-thick glass floor, under which the laser heat source was aligned. The thermal stimulus (50 • C) was applied from the laser radiant heat source. The withdrawal response time (latency) to the heat stimulus was measured (in seconds). The onset of the heat stimulus activated a timer that stopped automatically when the evoked paw withdrawal was detected. Three measurements of latency were made and averaged for each hindpaw and for each rat. To minimize sensitization, the rodent hindpaws were tested alternately, with 5 min intervals between stimuli on the same hindpaw.
Plasma cytokine expression profiles
At the end of the experiments, all animals were killed with an overdose of pentobarbital (60 mg kg −1 , I.P.). Under terminal anaesthesia, the caudal vena cava was transected to collect blood for the cytokine enzyme-linked immunosorbent assay (ELISA).
Immediately afterwards, transcardiac perfusion was performed with after being blank corrected, the mean ± SD was calculated for each sample and then appropriate statistical analysis performed.
Statistical analysis
The behavioural data were normally distributed and were therefore expressed as means ± SD. A repeated-measures ANOVA followed by
Tukey's pairwise comparison were used to analyse the behavioural data for each of our five time points with a full 16 animal data sets (Minitab Inc., State College PA, USA). For plasma cytokine analysis, a general linear model followed by Tukey's post hoc test was performed (Minitab Inc.). Statistical significance was defined as P ≤ 0.05, and the significance level is indicated on the graphs as follows: *P < 0.05; **P < 0.01 and ***P < 0.001.
RESULTS
1400W limits development of mechanical hypersensitivity after L5-SNA
To determine whether reducing iNOS-mediated NO concentrations with 1400W would attenuate mechanical hypersensitivity/allodynia associated with nerve injury, we measured the PWT to a mechanical stimulus (using an automated von Frey-type system; see Methods). The data were collected before and at several time points after L5-SNA in SNA rats treated with 1400W (1400W group) and in vehicle-treated SNA rats. There was a significant effect of treatment (F 1,56 = 8.86; on mechanical hypersensitivity and a significant interaction between treatment and time (F 3,56 = 3.64; P < 0.05).
1400W treatment increases the plasma concentrations of IL-1 , IL-1 and IL-10 cytokines in L5-SNA rats
Having established that 1400W limits heat and mechanical hypersensitivity in SNA rats, we examined our hypothesis that 1400W might exert its analgesic effects by altering the concentrations and ratios of pro-and anti-inflammatory/nociceptive cytokines. To investigate this, we analysed plasma concentrations of 12 cytokines (IL-1 , IL-1 , IL-2,
IL-4, IL-6, IL-10, IL-12, IL-13, IFN-, TNF-, GM-CSF and RANTES).
Eight of the 12 measured cytokines (IL-1 , IL-1 , IL-2, IL-4, IL-6, IL-10, IL-12 and IFN-) were significantly (P < 0.05) upregulated postaxotomy when compared with naive rats, as shown in Figure 3 . In addition, when examining the L5-SNA-treated rats, 1400W treatment postsurgery caused a significant increase in the plasma concentrations of IL-1 (P < 0.05), IL-1 (P < 0.01) and IL-10 (P < 0.01) when compared with the vehicle group.
DISCUSSION
In this study, we investigated, for the first time, whether the selective iNOS inhibitor, 1400W, limits pain hypersensitivity in the rat L5-SNA model of PNP. We found that 1400W administered I.P. at 8 h intervals starting at 18 h post-SNA is more effective in preventing development of heat hypersensitivity/hyperalgesia than mechanical hypersensitivity/allodynia. The L5-SNA model itself is known to induce the release of several inflammatory cytokines, as in human counterparts (Strong, Xie, Coyle, & Zhang, 2012) , but the interesting aspect of the present study is that compared with the vehicle-treated SNA rats,
1400W increased the plasma concentrations of an anti-inflammatory cytokine (IL-10) and the pro-inflammatory cytokines (IL-1 and IL-1 )
in the SNA rats.
1400W limits the development of both mechanical and heat hypersensitivity in SNA rats
The L5-SNA model used in the present study is one of the most widely used models of PNP; numerous studies have shown this model to exhibit long-lasting (>8 weeks) behavioural signs of mechanical allodynia and heat hyperalgesia (Chung et al., 2004; Jaggi, Jain, & Singh, 2011) . As reported previously , these two evoked pain behaviours were indicated by significant decreases in the mean PWT from a mechanical stimulus and in the mean paw withdrawal latency from a noxious heat stimulus, respectively. The most significant finding of the present study is that 1400W prevented the development of both heat hypersensitivity/hyperalgesia and mechanical hypersensitivity/allodynia, albeit to different extents.
Fluctuations in the release of pro-and anti-inflammatory cytokines and the altered balance between these cytokines at different time points could underlie why we observed a significant reduction at only one time point in the mechanical hypersensitivity study. A limitation of the present study was that cytokine concentrations were measured only at the end point, as outlined in the Methods, and it would be very interesting to explore the temporal profile of all 12 cytokines measured over time. This pain hypersensitivity is believed to result, at least in part, from hyperexcitability of primary afferent dorsal root ganglion , 2006; Iadecola, Zhang, Xu, Casey, & Ross, 1995; Levy & Zochodne, 1998; Levy, Höke, & Zochodne, 1999; Martucci et al., 2008; Parmentier et al., 1999; Perez-Asensio et al., 2005) . Although neuronal NOS has a protective role in axotomized DRG neurons (Thippeswamy & Morris, 1997 Thippeswamy et al., 2004) , the excessive NO produced from glia and infiltrated macrophages after peripheral nerve injury is known to sensitize both injured L5 and neighbouring uninjured L4 DRG neurons, in addition to spinal cord neurons (Scholz For all cytokines measured, there were no significant changes in cytokine concentrations between the naive + vehicle and the naive + 1400W; however, in the pain states (denoted by L5-SNA underneath), 1400W caused a significant increase in the median levels of the pro-inflammatory cytokines interleukin (IL)-1 (P < 0.05) and IL-1 ( ** P < 0.01) and a highly significant increase ( *** P < 0.001) in the anti-inflammatory cytokine IL-10 compared with the vehicle group. The figure also shows how eight of the 12 cytokines examined were significantly higher in L5-SNA rats compared with the naive animals. The statistical analysis was carried out using the general linear model and Tukey's post hoc test (significance denoted as * P < 0.05; naive + vehicle n = 3; naive + 1400W n = 3; L5-SNA + vehicle n = 6; and L5-SNA + vehicle n = 6) & Woolf, 2007) . Given that we have previously shown 1400W to suppress hyperexcitability of brain neurons for a prolonged period when administered soon after brain insult (Puttachary et al., 2016) , it is possible that 1400W exerts its analgesic effects by reducing the sensitizing effects of NO on the uninjured L4 DRG neurons. However, a central mechanism of 1400W action by way of interfering with the central sensitization processes cannot be excluded, because we have demonstrated that 1400W crosses the blood-brain barrier (BBB; Puttachary et al., 2016) .
Our findings that 1400W reduced neuropathic pain behaviours in the SNA rats are consistent with those of previous studies showing that blocking iNOS by intrathecal administration of 1400W before induction of inflammation reduced inflammatory hyperalgesia in two experimental rat models of inflammatory pain (Tang et al., 2007) and that 1400W reduced inflammatory pain in a rat model of arthritis when administered at a prophylactic dose (Rocha et al., 2002) . The dosing regimen of 1400W tested in the present study is based on the pharmacokinetic profile of 1400W and on the previous studies showing 1400W to be inefficient if given at intervals of >9 h (Parmentier et al., 1999; Perez-Asensio et al., 2005) .
1400W increases plasma concentrations of inflammatory cytokines in SNA rats
In the present study, we have investigated the plasma concentrations of 12 commonly known cytokines in SNA rats treated with 1400W
because nerve injury-induced cytokines are expected to be released into the circulation. 1400W has previously been shown to ameliorate the pathogenesis of numerous neurological conditions (JafarianTehrani et al., 2005; Parmentier et al., 1999; Pearse et al., 2003) , and its similar structure and molecular weight to L-arginine suggest that it is BBB permeable. Indeed, we have previously demonstrated that 1400W can cross the BBB and exert its effects in rats by reducing the serum albumin and 3-nitrotyrosine levels in the hippocampus in the rat model of temporal lobe epilepsy (Puttachary et al., 2016) . Another study, by Ryu and McLarnon (2006) , outlined how 1400W can prevent BBB leakiness and reduce 3-nitrotyrosine levels in the hippocampus and is effective in modulating the target molecules within the brain and therefore able to cross BBB. The effects of 1400W reported in the present study also imply that this selective inhibitor of iNOS might also act, at least in part, in the periphery, although the plasma studies carried out here investigated the potential systemic effects of 1400W.
We found that, of the 12 cytokines examined, the levels of IL-1 , IL-10 and IL-1 were significantly elevated in the 1400W-treated SNA rats.
One possible mechanism for the effectiveness of 1400W in limiting the development of heat hyperalgesia and mechanical allodynia in SNA rats is by altering the balance between the pro-and and antiinflammatory cytokines. This is because both IL-1 and IL-10 are typically thought to have anti-nociceptive effects (Vale et al., 2003; Wang et al., 2012; Willemen et al., 2014; Zychowska et al., 2013) .
However, IL-1 is a widely reported pro-inflammatory mediator/pronociceptive .
The roles of IL-1 and IL-1 in nociceptive signalling have not been well characterized, but IL-1 expression levels are upregulated after nerve injury. However, a study by Mika et al. (2008) found that, contrary to what might be expected with a pro-inflammatory cytokine, administration of IL-1 had both anti-allodynic and antihyperalgesic properties (Kras, Dong, & Winkelstein, 2014; Rothman & Winkelstein, 2010) . Interleukin-1 and IL-1 have both been shown to cause increased expression of substance P in DRG neurons in vitro (Skoff, Zhao, and Adler (2009) . These findings are difficult to reconcile with the proposed anti-nociceptive and pro-inflammatory role for IL-1 , because substance P is involved in the generation of neurogenic inflammation and is widely considered to be an algogenic substance, although low doses of substance P have been reported to produce analgesia in a rodent pain model (Frederickson, Burgis, Harrell, and Edwards (1978) . The results presented in the present study, showing increased plasma concentrations of IL-1 in SNA rats compared with naive rats, are consistent with those of previous studies of peripheral nerve injury (Sommer & Kress, 2004; Sweitzer, Colburn, Rutkowski, & DeLeo, 1999; Uceyler & Sommer, 2008; Zhang & An, 2007) . Our findings of elevated levels of IL-1 in SNA rats treated with 1400W are unexpected because IL-1 is considered to be a pro-nociceptive factor , and its upregulation is expected to exacerbate and not ameliorate neuropathic pain symptoms. However, IL-1 has been shown by some also to possess anti-nociceptive properties (Souter, Garry, & Tanelian, 2000) . Zychowska et al. (2013) , and to mediate both antiinflammatory and anti-nociceptive functions (Austin & Moalem-Taylor, 2010 ). Based on these findings and on our findings of elevated levels of IL-10 in SNA rats treated with 1400W, one mechanism by which 1400W could prevent development of heat hyperalgesia and mechanical allodynia after L5-SNA is by way of increasing IL-10 concentrations in the microenvironment of uninjured L4 DRG neurons. These could, in turn, reduce levels of pro-inflammatory mediators and therefore the neuroinflammation associated with SNA.
It is noteworthy, however, that any given cytokine may behave as a pro-as well as an anti-inflammatory cytokine depending on various factors, including its local concentration, its target cell or even the experimental model (Cavaillon, 2001) . The ultimate outcome of any cytokine signalling is also dependent on the type of cytokine receptor being expressed and activated. For example, activation of IL-1 type I receptor mediates the inflammatory action of IL-1, whereas type II receptor activation suppresses IL-1 binding activity (Arend, 1991; Kuno & Matsushima, 1994) , suggesting that mere upregulation of ligands does not necessarily result in a change of target cell functions.
But in light of these data and the behavioural study carried out on these L5-SNA-treated rats, it is plausible that 1400W might function by increasing the anti-nociceptive mediators (IL-1 and IL-10) to counteract and balance the neuroimmune response and, in turn, reduce neuronal hypersensitivity.
Conclusion
In conclusion, NO is one of the most potent known pro-inflammatory species. We found that inhibiting NO synthesis with a highly specific iNOS inhibitor, 1400W, limits the development of heat and mechanical hypersensitivity in the L5-SNA model of PNP. The measurement of concurrent increases in IL-1 , IL-1 and IL-10 concentrations in the plasma of 1400W-treated rats suggests that iNOS contributes to the pathophysiology of PNP and that 1400W might exert its analgesic action by altering the balance between the pro-and anti-inflammatory cytokines. These data suggest that therapies targeting NO or its enzymes might be effective for treatment of PNP.
